Agomab Therapeutics NV (AGMB)
Market Open
11 Sep, 15:17
NASDAQ (NMS) NASDAQ (NMS) Primary $
13. 69
-0.25
-1.7934%
$
686.52M Market Cap
- P/E Ratio
- Div Yield
46,814 Volume
- Eps
$ 13.94
Previous Close 
Analysts:
Want to track AGMB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
AgomAb Therapeutics: High Risk, High Reward Stock
AgomAb Therapeutics offers high-risk, high-reward potential driven by two late-stage immunology drugs targeting large addressable markets. AGMB-129 (Crohn's disease) and AGMB-447 (IPF) have Fast Track and Orphan Drug designations, indicating significant unmet need and regulatory advantages. Strong backing from major pharma players and a high institutional ownership position, AGOM is a potential acquisition target upon successful trial outcomes.
Seekingalpha | 3 months ago
